Nugen's EziAutoJector receives NHS drug tariff approval

Executive Summary

• Nugen Medical Devices’ UK partner, EziAutoJector Ltd., received NHS Business Services Authority confirmation that the EziAutoJector® needle‑free insulin delivery device and accessories are approved for inclusion in the NHS drug tariff.
• The approval allows eligible diabetes patients to obtain the device at no cost under NHS‑funded care, with pharmacists reimbursed for dispensing it.
• The company will leverage existing wholesale distribution channels, a new direct‑to‑consumer e‑commerce platform, and targeted education programs to drive UK market adoption.

Key Details

• Approval Scope: Inclusion of the full EziAutoJector product line (device + accessories) in the NHS drug tariff for reimbursable dispensing.
• Patient Benefit: Eligible patients receive the needle‑free insulin delivery system at no out‑of‑pocket cost; each patient eliminates >1,000 single‑use insulin needles per year, reducing biohazard waste.
• Reimbursement Mechanism: Pharmacists will be reimbursed by NHS for dispensing EziAutoJector products in line with NICE guidelines that support personalized insulin delivery choices.
• Distribution Strategy:
• Existing supply through a major pharmaceutical wholesaler to high‑street pharmacies.
• Direct‑to‑patient sales via online pharmacy services and a new D2C e‑commerce channel for regions with prescribing restrictions.
• Commercial Initiatives: Targeted educational outreach to diabetes healthcare professionals, pharmacists, patients, and caregivers to raise awareness and drive adoption.
• Environmental Impact: Projected reduction of >1,000 single‑use needles per patient annually, supporting NHS sustainability goals.

Notable Quotes

“NHS reimbursement approval marks a significant step forward for EziAutoJector Ltd. and for Nugen Medical Devices,” said Liang Lin, chief executive officer of Nugen Medical Devices. “It enables people living with diabetes to benefit from needle‑free insulin delivery and supports clinicians in delivering truly individualized care with reimbursement making easy patient access.”